Hematological morbidity and management in neonates with hemolytic disease due to red cell alloimmunization.

Mirjam E A Rath, Vivianne E H J Smits-Wintjens, Frans J Walther, Enrico Lopriore

Journal: Early human development 2012;87(9):583-8

PMID: 21798676

Full Text on Elsevier Science View on PubMed

Abstract

Treatment of severe anemia with intrauterine red cell transfusions in fetuses with red cell alloimmunization has led to a dramatic increase in perinatal survival. Due to this increased survival focus is nowadays shifting towards improving postnatal treatment options. Phototherapy, exchange transfusions and intravenous immunoglobulin are used to treat hyperbilirubinemia and prevent kernicterus. Postnatal treatment of anemia consists of top-up transfusions, supplements to support erythropoiesis such as folic acid and iron, and occasionally erythropoietin treatment. In addition to anemia, other hematological complications such as thrombocytopenia, coagulation disturbances, leucopenia and iron overload have been reported. This review focuses on the hematological morbidity in neonates with red cell alloimmunization and summarizes the current evidence on management options.

Address: Division of Neonatology, Department of Pediatrics, Leiden University Medical Center, PO Box 9600, 2300 RC, Leiden, The Netherlands. [email protected]

DOI: 10.1016/j.earlhumdev.2011.07.010

Link outs

Free resources

Medical:

https://medlineplus.gov/rhincompatibility.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Anemia, Blood Coagulation, Blood Transfusion, Blood Transfusion, Intrauterine, Dietary Supplements, Erythroblastosis, Fetal, Humans, Infant, Newborn, Morbidity, Phototherapy, Thrombocytopenia